Your browser doesn't support javascript.
loading
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.
Richardson, Nicholas C; Kasamon, Yvette; Pazdur, Richard; Gormley, Nicole.
Afiliação
  • Richardson NC; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: nicholas.richardson@fda.hhs.gov.
  • Kasamon Y; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Pazdur R; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Gormley N; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Lancet Oncol ; 23(5): 563-566, 2022 05.
Article em En | MEDLINE | ID: mdl-35429996
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Fosfatidilinositol 3-Quinases Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Fosfatidilinositol 3-Quinases Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article